Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

After Berkshire Bought Teva Pharmaceutical Stock, Should Others Follow Suit?

By Chris Lau, InvestorPlace Contributor

TEVA stock has multiple headwinds, including high debt and weakeneing Copaxone sales. But TEVA should benefit from promising new products.

Why It Is About Time That Take-Two Stock Bounces Back

By Chris Lau, InvestorPlace Contributor

The Street is undervaluing the value of TTWO's games and of Take-Two stock. TTWO looks poised to bounce back in 2020.

Hot Growth Ahead for LPSN Stock in 2019

By Chris Lau, InvestorPlace Contributor

LivePerson shares are at a yearly high and shows no sign of pulling back. Why are investors buying up LPSN stock?

Invitae Stock Is Hot Right Now And Here’s Why It Will Only Get Hotter

By Chris Lau, InvestorPlace Contributor

Even after issuing shares, NVTA stock is in high demand as the genetic testing firm reported a strong quarter

Reasons to Buy Fitbit Stock If It Dips

By Chris Lau, InvestorPlace Contributor

Fitbit reported slightly lower revenue declines and solid cost control. Why is FIT stock worth another look? It's the smartwatches.

Load More